Top Page
Inoviq Ltd
(Sydney:IIQ)
Inoviq Ltd (IIQ) vs. iShares MSCI Australia ETF (EWA)
Inoviq Ltd Business Overview & Revenue Model
Inoviq Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82M | 1.82M | 535.12K | 398.19K | 276.75K | 1.27M |
| Gross Profit | -1.56M | -1.56M | 454.11K | -1.04M | -1.88M | -2.21M |
| EBITDA | -6.16M | -6.16M | -6.34M | -9.32M | -19.39M | -6.05M |
| Net Income | -6.93M | -6.93M | -6.55M | -8.97M | -18.20M | -11.15M |
Balance Sheet | ||||||
| Total Assets | 18.46M | 18.46M | 21.71M | 21.51M | 30.78M | 33.52M |
| Cash, Cash Equivalents and Short-Term Investments | 6.52M | 6.52M | 9.23M | 7.81M | 15.39M | 5.00M |
| Total Debt | 376.19K | 376.19K | 776.54K | 730.71K | 998.69K | 1.26M |
| Total Liabilities | 1.74M | 1.74M | 1.72M | 1.89M | 2.49M | 4.46M |
| Stockholders Equity | 16.71M | 16.71M | 19.99M | 19.62M | 28.29M | 29.06M |
Cash Flow | ||||||
| Free Cash Flow | -4.77M | -4.77M | -4.50M | -7.32M | -6.47M | -6.05M |
| Operating Cash Flow | -4.66M | -4.66M | -4.32M | -7.02M | -6.06M | -5.26M |
| Investing Cash Flow | -104.00K | -104.00K | -174.34K | -292.27K | -411.90K | 2.64M |
| Financing Cash Flow | 2.05M | 2.05M | 5.91M | -267.98K | 16.87M | 286.48K |
Inoviq Ltd Technical Analysis
Inoviq Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$50.59M | -13.18 | -501.54% | ― | ― | 56.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$44.17M | -6.06 | -97.79% | ― | ― | 23.85% | |
42 Neutral | AU$154.53M | -14.60 | -111.23% | ― | 12.96% | 40.81% | |
40 Underperform | AU$37.48M | -1.83 | -36.16% | ― | 62.81% | 16.37% | |
38 Underperform | AU$51.38M | -5.78 | -37.78% | ― | 2.33% | 12.50% |
Inoviq Ltd Corporate Events
Inoviq Ltd has notified the market of the issue of 700,000 unquoted options under its employee incentive scheme, recorded as Appendix 3G with the ASX. The options, which have various expiry dates and exercise prices and are not intended to be quoted on the exchange, form part of Inoviq’s remuneration and retention strategy for staff, underscoring the company’s use of equity-based incentives to align employees with long-term shareholder value and operational goals.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ has appointed internationally recognised exosome and cell therapy specialist Dr Rebecca Lim as Chief Scientific Officer, effective 12 January 2026, to lead its research and development strategy across preclinical, clinical and regulatory programs in exosome capture tools, diagnostics and therapeutics. Lim’s more than 20 years’ experience in translational research, advanced therapy development and regulatory navigation in Australia and the US is expected to accelerate INOVIQ’s CAR-exosome therapeutic pipeline toward first-in-human studies and strengthen the company’s global leadership ambitions in exosome technologies, while founder Professor Greg Rice transitions to a part-time role as Founding Scientist and Advisor to ensure continuity of scientific oversight and diagnostics leadership during the next phase of growth.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ has reported positive in vivo proof-of-concept data for its EGFR-targeted CAR-NK exosome therapy in a triple-negative breast cancer mouse model, with its CAR-NK-EVs delivering a 61.5% tumour reduction over 28 days, 100% survival in treated mice, and a favourable safety profile compared with controls. The study also showed improved precision targeting with reduced non-specific liver accumulation, validating the company’s EXO-ACE manufacturing platform and underpinning a newly filed provisional patent on CAR-targeting and exosome purification, which strengthens INOVIQ’s intellectual property position and supports the advancement of its off-the-shelf, cell-free immunotherapy platform for hard-to-treat solid tumours.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
Inoviq Ltd has notified the ASX that 2.3 million options (security code IIQAE), which were due to expire on various dates and at various exercise prices, have lapsed because the conditions required for conversion into securities were not, or could no longer be, satisfied. The cessation of these options slightly reduces the company’s pool of potential equity on issue, which may marginally affect future dilution expectations for existing shareholders but has no immediate impact on current issued share capital.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Limited has announced that director David Williams ceased to be a director on 18 December 2025, lodging a final director’s interest notice with the ASX in accordance with listing requirements. The notice details Williams’ remaining interests in INOVIQ securities, including substantial holdings of ordinary fully paid shares held via several private entities, employee options and listed options, clarifying his equity position for investors and ensuring continued transparency around major shareholder and governance changes following his departure from the board.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Ltd has announced a leadership transition with David Williams stepping down as Chairman, effective December 18, 2025, and Peter Gunzburg taking over the role. Gunzburg emphasized the company’s readiness to advance its well-funded product development strategy, marking a significant phase in achieving milestones to benefit patients, partners, and shareholders.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Ltd held its 2025 Annual General Meeting where all resolutions were passed by poll, reflecting strong shareholder support. This outcome is significant for the company’s strategic direction and may positively influence its market positioning in the cancer diagnostics and therapeutics industry.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Ltd announced that Chairman David Williams will step down by year-end or upon the appointment of a new Chair, following the completion of a recent capital raising and the addition of a new Chinese cornerstone investor. Under Williams’ leadership, INOVIQ transitioned key programs from research to development, advanced its ovarian cancer test, and expanded commercialization of its exosome capture technology. The company is well-positioned to achieve its strategic objectives in the coming year, with a strengthened leadership team.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Ltd’s recent presentation highlights the company’s ongoing activities and strategic focus on exosome diagnostics and therapeutics. The announcement underscores the speculative nature of investments in the company, emphasizing that past performance is not indicative of future results, and that forward-looking statements are subject to change.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
Inoviq Ltd has announced a change in the director’s interest notice, specifically regarding Max Johnston. The director has acquired 85,714 ordinary fully paid shares through participation in a Share Purchase Plan, increasing his total holdings to 890,024 shares. This change reflects the director’s continued investment in the company, potentially signaling confidence in Inoviq’s future prospects.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
Inoviq Ltd has announced a new application for the quotation of 1,999,800 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to impact the company’s market presence by increasing its available securities for trading, potentially enhancing liquidity and investor interest.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
INOVIQ Ltd has successfully completed its share purchase plan, raising a total of A$0.7 million, contributing to a total capital raise of A$10.2 million alongside a recent placement to institutional investors. The funds will be allocated to accelerate the clinical validation and commercialization of the EXO-OC™ ovarian cancer test and to advance the preclinical development of the exosome therapeutic program for solid tumors, potentially enhancing the company’s market position in cancer diagnostics and therapeutics.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.